Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Charité Universitätsmedizin Berlin, Berlin, Germany.
Pharmacopsychiatry. 2023 Sep;56(5):188-196. doi: 10.1055/a-2117-5200. Epub 2023 Jul 28.
While lithium (Li) has been well established for the treatment of bipolar disorder, geriatric patients require special attention when it comes to issues of drug safety. Declining renal function, amongst other medical conditions, and polypharmacy may pose increased risks. Only a few previous studies have addressed the management of Li in geriatric patients.
Twenty-four German medical experts on geriatric medicine and Li treatment participated in a Delphi survey, consisting of two rounds of questionnaires and a final formulation of treatment recommendations. Three major issues of Li therapy were outlined: initiation of treatment, monitoring of ongoing therapy, and withdrawal due to medical reasons. Final recommendations were consented to at a threshold of at least 80% expert agreement.
Final consensus was achieved on 21 clinical recommendations. The approved recommendations covered aspects of necessary laboratory checks, concomitant medication, and target Li serum concentration in geriatric patients. Concerning the termination of Li therapy, an agreement was reached on the appropriate time span for tapering and on potential alternatives to Li. No consensus was achieved on whether concomitant dementia or frailty should be considered contraindications for Li treatment and the appropriate threshold of the estimated glomerular function rate for withdrawing Li.
According to the view of German experts, Li may be used in geriatric patients, but it should be monitored carefully. However, the lack of consent in several specific treatment situations underlines the need for research on specific issues of Li therapy.
虽然锂(Li)已被广泛用于治疗双相情感障碍,但在涉及药物安全性问题时,老年患者需要特别关注。肾功能下降等其他医疗条件和多种药物治疗可能会增加风险。只有少数先前的研究探讨了老年患者的 Li 治疗管理。
24 名德国老年医学和 Li 治疗专家参与了一项德尔菲调查,该调查由两轮问卷和最终的治疗建议组成。Li 治疗的三个主要问题概述如下:治疗开始、持续治疗监测和因医疗原因停药。至少 80%的专家同意作为达成最终建议的阈值。
最终达成了 21 项临床建议的共识。批准的建议涵盖了老年患者必要的实验室检查、伴随药物和目标 Li 血清浓度的方面。关于 Li 治疗的终止,专家们就逐渐减少的适当时间范围以及 Li 的潜在替代方案达成了一致。关于是否应将合并痴呆或虚弱视为 Li 治疗的禁忌症以及撤回 Li 的估计肾小球滤过率的适当阈值,未达成共识。
根据德国专家的观点,Li 可用于老年患者,但应密切监测。然而,在一些特定治疗情况下缺乏共识,突出了对 Li 治疗具体问题进行研究的必要性。